[1] |
Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis[J]. Nat Rev Microbiol, 2009, 7 (7): 526-536.
|
[2] |
Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)[J]. Infect Control Hosp Epidemiol, 2010, 31 (5): 431-455.
|
[3] |
Leffler DA, Lamont JT. Clostridium difficile infection[J]. N Engl J Med, 2015, 372 (16): 1539-1548.
|
[4] |
Kelly CP, Lamont JT. Clostridium difficile-more difficult than ever[J]. N Engl J Med, 2008, 359 (18): 1932-1940.
|
[5] |
Bignardi GE. Risk factors for Clostridium difficile infection[J]. J Hosp Infect, 1998, 40 (1): 1-15.
|
[6] |
Blot E, Escande MC, Besson D, et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics[J]. J Hosp Infect, 2003, 53 (3): 187-192.
|
[7] |
Jayatilaka S, Shakov R, Eddi R, et al. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors[J]. Ann Clin Lab Sci, 2007, 37 (3): 241-247.
|
[8] |
Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection[J]. Clin Infect Dis, 2008, 46 (Suppl 1): S12-S18.
|
[9] |
Mcfarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. Difficile-associated diarrhea in a cohort of hospitalized patients[J]. J Infect Dis, 1990, 162 (3): 678-684.
|
[10] |
Kim SC, Seo MY, Lee JY, et al. Advanced chronic kidney disease: a strong risk factor for Clostridium difficile infection[J]. Korean J Intern Med, 2016, 31 (1): 125-133.
|
[11] |
叶关胜,许文芳,金法祥,等.难辨梭菌相关性腹泻老年患者68例免疫功能分析[J/CD].中华危重症医学杂志:电子版,2015,8(5):318-320.
|
[12] |
单仁飞,崔可,张远怀,等.消化道肿瘤术后合并肾上腺皮质功能减退15例临床分析[J/CD].中华危重症医学杂志:电子版,2012,5(4):266-268.
|
[13] |
Al-Tureihi FI, Hassoun A, Wolf-Klein G, et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients[J]. J Am Med Dir Assoc, 2005, 6 (2): 105-108.
|
[14] |
Salazar-Kagunye R, Shah A, Loshkajian G, et al. Association of decreased serum protein fractions with clostridium difficile infection in the acute care setting: a case-control study[J]. Biomark Med, 2012, 6 (5): 663-669.
|
[15] |
Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality[J]. N Engl J Med, 2005, 353 (23): 2442-2449.
|
[16] |
Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis[J]. Am J Dis Child, 1935, 49(2): 390-402.
|
[17] |
Antharam VC, Mcewen DC, Garrett TJ, et al. An integrated metabolomic and microbiome analysis identified specific gut microbiota associated with fecal cholesterol and coprostanol in Clostridium difficile infection[J]. PLoS One, 2016, 11 (2): e0148824.
|
[18] |
Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients[J]. Expert Rev Anti Infect Ther, 2010, 8 (10): 1113-1119.
|
[19] |
Fanali G, di Masi A, Trezza V, et al. Human serum albumin: from bench to bedside[J]. Mol Aspects Med, 2012, 33 (3): 209-290.
|
[20] |
Nazha B, Moussaly E, Zaarour M, et al. Hypoalbuminemia in colorectal cancer prognosis: nutritional marker or inflammatory surrogate?[J]. World J Gastrointest Surg, 2015, 7 (12): 370-377.
|
[21] |
Jafari NV, Kuehne SA, Minton NP, et al. Clostridium difficile-mediated effects on human intestinal epithelia: Modelling host-pathogen interactions in a vertical diffusion chamber[J]. Anaerobe, 2016 (37): 96-102.
|
[22] |
Mcdermott AJ, Falkowski NR, Mcdonald RA, et al. Interleukin-23 (IL-23), independent of IL-17 and IL-22, drives neutrophil recruitment and innate inflammation during Clostridium difficile colitis in mice[J]. Immunology, 2016, 147 (1): 114-124.
|
[23] |
Mcmillan DC, Watson WS, O'gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss[J]. Nutr Cancer, 2001, 39 (2): 210-213.
|
[24] |
Don BR, Kaysen GA. Assessment of inflammation and nutrition in patients with end-stage renal disease[J]. J Nephrol, 2000, 13 (4): 249-259.
|
[25] |
Wakamura K, Kudo SE, Miyachi H, et al. Characteristics of colorectal tumours in asymptomatic patients with negative immunochemical faecal occult blood test results[J]. Mol Clin Oncol, 2015, 3 (5): 1019-1024.
|
[26] |
Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects[J]. Cardiovasc Diabetol, 2010 (9): 9.
|
[27] |
Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation[J]. Diabetes, 2011, 60 (10): 2441-2449.
|
[28] |
Offermanns S. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors[J]. Annu Rev Pharmacol Toxicol, 2014 (54): 407-434.
|
[29] |
Yonezawa T, Kurata R, Yoshida K, et al. Free fatty acids-sensing G protein-coupled receptors in drug targeting and therapeutics[J]. Curr Med Chem, 2013, 20 (31): 3855-3871.
|
[30] |
Winer DA, Luck H, Tsai S, et al. The intestinal immune system in obesity and insulin resistance[J]. Cell Metab, 2016, 23 (3): 413-426.
|
[31] |
Garrett WS. Cancer and the microbiota[J]. Science, 2015, 348 (6230): 80-86.
|
[32] |
Patterson E, Ryan PM, Cryan JF, et al. Gut microbiota, obesity and diabetes[J]. Postgrad Med J, 2016, 92 (1087): 286-300.
|
[33] |
Geurts L, Neyrinck AM, Delzenne NM, et al. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics[J]. Benef Microbes, 2014, 5 (1): 3-17.
|